Evolutionary Genomics, Inc. Stock: price and insider trades · United States
Evolutionary Genomics, Inc.: what insiders have been doing
We have very little insider data for Evolutionary Genomics, Inc. so far: the most recent filing dates from 25 May 2022. With so few records, no pattern can be drawn yet. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2021FY ended December 2021 · cache
- 78,571 shares@ US$0.70Common StockSEC:0001079973-22-000667:1
- 52,381 shares@ US$0.70Common StockSEC:0001079973-22-000665:1
- 15,714 shares@ US$0.70100.0% of flowCommon StockSEC:0001079973-22-000663:1
- 20,000 shares@ €0.5149100.0% of flowCommon StockSEC:0001079973-22-000663:0
- 66,667 shares@ €0.5149100.0% of flowCommon StockSEC:0001079973-22-000665:0
- 100,000 shares@ €0.5149100.0% of flowCommon StockSEC:0001079973-22-000667:0
- 37,500 shares0Common StockSEC:0001553350-21-000447:1
- 37,500 shares0Common StockSEC:0001553350-21-000447:0
- 15,000 shares0Common StockSEC:0001553350-21-000002:0
- 15,000 shares0Common StockSEC:0001553350-21-000002:1
- 120,752 sharesCommon StockSEC:0001553350-16-002456:0
- 1,530,901 shares@ US$0.021Common StockSEC:0001553350-14-001204:0
- 5,201,423 shares@ US$0.021Common StockSEC:0001553350-14-001175:0
13 of 13 declarations
About Evolutionary Genomics, Inc.
Evolutionary Genomics, Inc. is a U.S.-based biotechnology company with a scientific and intellectual-property-driven business model, and it is identified through the U.S. listed-company ecosystem on the NYSE/NASDAQ market context provided in the request. The company is domiciled in the United States and has historically focused on gene discovery and trait validation for agricultural and biological applications. Its SEC filings show that the business was originally incorporated in 1990 as Fonahome Corporation, later reorganized, and renamed Evolutionary Genomics, Inc. in 2015 following a merger transaction. The company’s headquarters are described in filings as being at the office of its CEO, with business addresses in Colorado, including Castle Rock and Longmont in historical SEC documents. ([sec.gov](https://www.sec.gov/Archives/edgar/data/884363/000155335017000164/fnam_10k.htm))
At the core of the company’s strategy is the Adapted Traits Platform (ATP), a proprietary research platform designed to identify commercially valuable genes associated with desirable traits in plants, animals, and, more broadly, genomics research. The company describes a process that begins by screening for genes that have undergone adaptive evolution, then narrowing functional genomics work toward traits with potential commercial utility. This positioning gives Evolutionary Genomics a niche role in trait discovery, rather than a mass-market product role. Its patent portfolio includes methods for identifying evolutionarily significant sequence changes and methods for producing transgenic plants containing evolutionarily significant polynucleotides, reinforcing the company’s reliance on scientific know-how and defensible IP. ([sec.gov](https://www.sec.gov/Archives/edgar/data/884363/000155335017000164/fnam_10k.htm))
Read moreShow less
From a business-line perspective, the company appears to operate as a research and licensing-oriented biotech platform. Historical SEC disclosures indicate that it has worked on crop-related programs aimed at improving corn and rice yield, tomato sugar content and salt tolerance, and soybean pest/disease resistance, among other traits. The company has also generated revenue through grants and commercial research contracts, with some agreements potentially including licensing provisions upon commercialization. That structure suggests a hybrid model where near-term cash generation may come from research services, while long-term upside depends on successful commercialization of discoveries or licensing outcomes. ([sec.gov](https://www.sec.gov/Archives/edgar/data/884363/000155335017000164/fnam_10k.htm))
Competitively, Evolutionary Genomics should be viewed as a specialist niche player in the trait-discovery segment of biotechnology and ag-biotech. It is not presented as a vertically integrated agricultural major; rather, it competes on the quality of its platform, the specificity of its gene-discovery pipeline, and the commercial relevance of the traits it can identify. Its collaborations with universities and public-sector or foundation partners point to a research network model, which can be valuable for validation and platform development. ([sec.gov](https://www.sec.gov/Archives/edgar/data/884363/000155335017000164/fnam_10k.htm))
A notable historical milestone was the 2015 merger/reorganization that effectively made Evolutionary Genomics the surviving operating business within the public shell, followed by ongoing SEC reporting. Publicly available information suggests a small-cap, high-risk profile with limited operating scale and a heavy dependence on research execution, funding access, and IP monetization. For French, Belgian, and Swiss investors, the stock should therefore be interpreted as a speculative U.S. biotech micro-cap on the NYSE/NASDAQ universe, with upside tied to platform validation rather than diversified commercial revenues. ([sec.gov](https://www.sec.gov/Archives/edgar/data/884363/000155335017000164/fnam_10k.htm))
